Equities
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)227.00
  • Today's Change-8.60 / -3.65%
  • Shares traded344.76k
  • 1 Year change-18.52%
  • Beta1.7759
Data delayed at least 15 minutes, as of Dec 06 2022 15:59 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

  • Revenue in DKK (TTM)2.40bn
  • Net income in DKK-599.24m
  • Incorporated1992
  • Employees917.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bonesupport Holding AB195.30m-48.88m3.73bn92.00--19.66--19.12-1.12-1.124.464.330.80580.55436.403,119,554.00-20.17-35.30-24.45-44.5789.9487.87-25.03-84.283.86-65.330.0611--17.7115.2715.66--19.98--
Calliditas Therapeutics AB275.61m-431.71m3.90bn169.00--7.11--14.15-12.18-12.187.7313.630.249725.163.346,136,621.00-39.13-31.46-44.45-34.6890.49---156.69-288.514.42--0.3916--26,141.08---15.41--145.12--
Swedencare AB (publ)1.08bn63.22m3.98bn506.0071.490.733516.873.680.51730.517310.7950.410.22632.439.235,680,857.001.324.781.355.0751.5057.825.8411.942.46-521.070.186632.49221.7770.4663.7641.06----
Surgical Science Sweden AB510.45m94.14m5.54bn233.0050.501.8742.5010.853.173.1715.7485.750.1741.886.023,589,120.003.213.413.403.6766.8778.8018.4415.422.3434.850.04280.00249.9847.90452.6692.434.25--
Nykode Therapeutics ASA250.50m-139.93m5.69bn147.00--4.81--22.72-0.6136-0.61361.165.720.1642--5.403,446,915.00-9.1725.30-10.2827.55-----55.8646.19----0.03---84.20311.05-106.29--157.24--
BioGaia AB704.87m185.51m5.79bn195.0032.414.7828.858.222.702.7010.2618.310.5017----6,202,617.0013.2018.7014.1621.2772.6974.1826.3226.20----0.0075.305.097.999.204.222.60-0.6484
AddLife AB6.05bn405.98m9.50bn2.20k24.333.0110.991.574.874.8772.6439.400.76933.966.524,932,631.005.189.038.4817.1037.6135.746.737.570.44186.130.541734.1751.57--38.78------
Camurus AB592.78m19.37m10.24bn170.00564.0715.53367.6717.270.48150.481515.5517.490.76430.93196.595,885,939.002.50-27.663.09-33.8288.1386.733.27-84.903.0347.330.0253--78.7439.4945.93--1.59--
Zealand Pharma A/S100.60m-976.09m10.26bn203.00--25.10--101.94-22.13-25.892.277.910.07310.10021.76283,371.80-70.93-27.88-88.11-32.4994.20---970.30-275.483.69--0.575---69.28-14.0110.84--53.47--
BioArctic AB157.13m18.88m15.59bn56.001,011.4232.70548.3599.210.30750.30752.609.510.2509----4,712,408.003.015.333.317.2586.7587.9312.0124.30----0.01237.21-62.88-26.18-74.83--8.13--
Bavarian Nordic A/S2.40bn-599.24m16.67bn917.00--2.39--6.93-8.68-8.6836.3098.470.21462.614.963,167,704.00-5.35-2.42-6.74-2.9337.8545.79-24.92-11.371.71-1.640.3719--2.4613.52-267.47--63.17--
Vitrolife AB1.97bn239.95m18.71bn1.07k77.291.6839.879.502.632.6321.83121.020.21964.018.746,775,719.002.688.882.789.5555.8363.5312.2224.081.5010.920.118723.2234.9414.4518.8712.3635.349.00
ALK-Abello A/S4.36bn333.00m20.68bn2.60k67.745.7135.484.741.511.5119.6817.870.72681.326.771,718,959.005.55-0.51157.21-0.616362.3958.117.64-0.81181.00--0.1419--12.175.44776.00-4.103.17--
Data as of Dec 06 2022. Currency figures normalised to Bavarian Nordic A/S's reporting currency: Danish Krone DKK

Institutional shareholders

15.96%Per cent of shares held by top holders
HolderShares% Held
Invesco Advisers, Inc.as of 31 Oct 20222.93m4.14%
The Vanguard Group, Inc.as of 04 Nov 20221.94m2.75%
Norges Bank Investment Managementas of 31 Dec 20211.72m2.43%
Dimensional Fund Advisors LPas of 04 Nov 20221.13m1.60%
BlackRock Fund Advisorsas of 03 Nov 2022935.14k1.32%
Nykredit Bank A/S (Investment Management)as of 30 Sep 2022697.20k0.99%
Allianz Global Investors GmbHas of 31 Jul 2022522.52k0.74%
Polar Capital LLPas of 28 Oct 2022505.40k0.72%
DNB Asset Management ASas of 30 Sep 2022457.97k0.65%
Max Mitteregger Kapitalf�rvaltning ABas of 31 Dec 2016442.44k0.63%
More ▼
Data from 31 Dec 2016 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.